EMA Authorised: Lumykras (sotorasib) — Amgen Europe B.V.

View source ↗

Summary

The EMA authorised Lumykras (sotorasib) for non-small-cell lung cancer. The decision includes a conditional approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lumykras (sotorasib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Amgen Europe B.V.. Decision date: 21/10/2024. Conditional approval